In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vivoryon Therapeutics N.V.

https://www.vivoryon.com/

Latest From Vivoryon Therapeutics N.V.

Asia Deal Watch: India’s Encube Targeted As Private Equity Interest In CDMOs Grows

Plus deals involving Y-Biologics/Pierre Fabre, Contera/Abzu, Chugai/Alebund, Catalyst/DyDo, Spergogenix/Abbiska, Nippon Gene/ERS Genomics, Simcere/Vivoryon, Dr. Reddy’s/Journey Medical and Innovent/Synaffix.

Deals Deal Watch

Vivoryon Brings 'Diversity' To Therapeutic Approach In Alzheimer’s

Ulrich Dauer, CEO Vivoryon Therapeutics, the new name for German biotech Probiodrug, talks to In Vivo about introducing more diversity into the Alzheimer’s disease pipeline.

Innovation Clinical Trials

Interview: Vivoryon Raises €43m After Alzheimer's Revival

New life has been breathed into Alzheimer's research following the reversal of fortunes for Biogen's aducanumab and Vivoryon is benefiting from the upturn in sentiment for the field.

Financing Companies

Vivoryon And MorphoSys Link To Accelerate Novel Small Molecule Checkpoint Silencing Approach

Vivoryon CEO explains how QPCTL-targeting small molecule technology will be tested for combination with MorphoSys’s tafasitamab to enhance cancer-killing efficacy.

ImmunoOncology Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Probiodrug AG
    • Vivoryon Therapeutics AG
UsernamePublicRestriction

Register